|
sars-cov-2 |
30 |
|
covid-19 |
25 |
|
antiviral |
18 |
|
coronavirus |
16 |
|
influenza a virus |
16 |
|
bunyavirales |
13 |
|
live attenuated vaccine |
13 |
|
sftsv |
12 |
|
2′-o-methyltransferase |
11 |
|
anthranilic acid |
11 |
|
broad spectrum |
11 |
|
endoplasmic reticulum |
11 |
|
human immunodeficiency virus |
11 |
|
mucosal immunity |
11 |
|
neutralizing antibodies |
11 |
|
nsp16 |
11 |
|
sterilizing immunity |
11 |
|
t-cell response |
11 |
|
animal experiment |
9 |
|
animal model |
9 |
|
antibody-dependent cell-mediated cytotoxicity |
9 |
|
bagg albino mouse |
9 |
|
clinical outcome |
9 |
|
controlled study |
9 |
|
genome mutation |
9 |
|
h1n1 influenza virus |
9 |
|
hemagglutinin |
9 |
|
human respiratory syncytial virus |
9 |
|
immune protection |
9 |
|
inactivated vaccine |
9 |
|
lethal mouse model |
9 |
|
lipidomics |
9 |
|
lung damage |
9 |
|
lung pathology |
9 |
|
mice |
9 |
|
phosphatidic acid phosphatases |
9 |
|
reverse genetics |
9 |
|
sars-cov-2 variants of concern |
9 |
|
25-hydroxycholesterol |
8 |
|
3clpro inhibitor |
8 |
|
allosteric-site inhibitor |
8 |
|
am580 |
8 |
|
animal models |
8 |
|
broad-spectrum antiviral treatment |
8 |
|
chemical genetics |
8 |
|
faci |
8 |
|
high throughput screening |
8 |
|
interferon |
8 |
|
betacoronavirus |
7 |
|
bioinorganic chemistry |
7 |
|
bismuth |
7 |
|
cell line |
7 |
|
combination therapy |
7 |
|
coronavirus infection |
7 |
|
corticosteroid |
7 |
|
endonuclease activity |
7 |
|
enzyme activation |
7 |
|
human |
7 |
|
inhibitor |
7 |
|
metabolic syndrome |
7 |
|
nsp14 exon and mtase |
7 |
|
nsp3 |
7 |
|
pan-a37s |
7 |
|
pan-a37s/i61t |
7 |
|
pan-a37s/v63i |
7 |
|
polymerase activity |
7 |
|
protease |
7 |
|
remdesivir |
7 |
|
treatment |
7 |
|
acyl-coa esters |
6 |
|
arabidopsis |
6 |
|
artenimol |
6 |
|
broxyquinoline |
6 |
|
eltrombopag |
6 |
|
entry |
6 |
|
epsc |
6 |
|
expanded potential stem cell |
6 |
|
fatty acids |
6 |
|
hexachlorophene |
6 |
|
huaiyangshan banyangvirus |
6 |
|
human trophoblast |
6 |
|
interactome |
6 |
|
jasmonate |
6 |
|
linolenic acid |
6 |
|
omacetaxine mepesuccinate |
6 |
|
oxylipins |
6 |
|
pathogenesis |
6 |
|
peptide |
6 |
|
regorafenib |
6 |
|
sfstv |
6 |
|
tick |
6 |
|
triclosan |
6 |
|
trophoblast organoid |
6 |
|
wounding |
6 |
|
acyl-coa-binding protein |
5 |
|
aim2 |
5 |
|
avian influenza a virus |
5 |
|
ba.2.12.1 |
5 |
|
ba.5.2 |
5 |
|
calcineurin |
5 |
|
cholesterol uptake |
5 |
|
clathrin adaptors |
5 |
|
ddx5 |
5 |
|
endocytosis |
5 |
|
enterovirus |
5 |
|
f486v |
5 |
|
glucose homeostasis |
5 |
|
h7n9 virus |
5 |
|
hnpcs |
5 |
|
hypercholesterolemia |
5 |
|
ifi16 |
5 |
|
inflammasome |
5 |
|
inflammasome activation |
5 |
|
keywords sars-cov-2 |
5 |
|
library |
5 |
|
low-density lipoprotein receptor |
5 |
|
mavs |
5 |
|
metabolic profiling |
5 |
|
nfat |
5 |
|
nlrp3 |
5 |
|
nsp1 |
5 |
|
pb1-f2 virulence factor |
5 |
|
rcan3 |
5 |
|
sars coronavirus |
5 |
|
transcript isoform |
5 |
|
animal reservoir |
4 |
|
antivirals |
4 |
|
bats |
4 |
|
companion cell |
4 |
|
endemic |
4 |
|
intestinal fat absorption |
4 |
|
lipid homeostasis |
4 |
|
mers-cov |
4 |
|
opda |
4 |
|
pandemic |
4 |
|
phloem exudates |
4 |
|
phospholipid-binding protein |
4 |
|
recycling endosome |
4 |
|
replicon |
4 |
|
sars-cov |
4 |
|
sieve elements |
4 |
|
single-cycle infectious virus |
4 |
|
vaccines |
4 |
|
2019 novel coronavirus |
3 |
|
2019 novel coronavirus (2019-ncov) |
3 |
|
adeno-associated virus |
3 |
|
dendritic cells |
3 |
|
flavivirus |
3 |
|
high-fat diet |
3 |
|
interferon signaling |
3 |
|
lipid metabolism |
3 |
|
macrophages |
3 |
|
novel coronavirus pneumonia (ncp) |
3 |
|
stat1 |
3 |
|
acyl-coa |
2 |
|
acyl-coa-binding proteins |
2 |
|
antiviral therapy |
2 |
|
arabidopsis thaliana |
2 |
|
arabidopsis thaliana acbp6 |
2 |
|
b. napus-rc cold tolerance |
2 |
|
blind docking |
2 |
|
brassica napus |
2 |
|
carrier proteins |
2 |
|
chemical similarity |
2 |
|
coronavirus vaccines |
2 |
|
developing seeds |
2 |
|
exine |
2 |
|
fluorescence |
2 |
|
freezing tolerance |
2 |
|
gene expression |
2 |
|
influenza |
2 |
|
keywords: coronavirus disease 2019 (covid-19) |
2 |
|
ligand-based virtual screening |
2 |
|
lipid analysis |
2 |
|
lipid trafficking |
2 |
|
lysophosphatidylcholine |
2 |
|
middle east respiratory syndrome coronavirus |
2 |
|
molecular dynamics simulations |
2 |
|
oil body |
2 |
|
pdlp8 |
2 |
|
pharmacophore models |
2 |
|
phloem |
2 |
|
phosphatidylcholine |
2 |
|
plasma membrane |
2 |
|
plasmodesmata |
2 |
|
pollen |
2 |
|
pollen tube |
2 |
|
pollen1 |
2 |
|
protein-protein interaction |
2 |
|
reproduction |
2 |
|
reversible lysophosphatidylcholine acyltransferase |
2 |
|
severe acute respiratory syndrome coronavirus (sars-cov) |
2 |
|
triacylglycerols |
2 |
|
virological diagnosis |
2 |
|
virus polymerase |
2 |
|
antibody complementarity-determining region |
1 |
|
anticancer nanometre-biomissiles |
1 |
|
basic amino acids |
1 |
|
blood circulation |
1 |
|
cirrhosis |
1 |
|
conditional potency |
1 |
|
consensus peptide sequences |
1 |
|
hepatitis b virus x protein |
1 |
|
hydrogen bond donors and acceptors |
1 |
|
leucine insulator |
1 |
|
liver cancer |
1 |
|
mouse model |
1 |
|
viral protein-derived toxic peptides |
1 |
